June’s pharmaceutical headlines reflect significant regulatory shifts, industry reorganization, and technological innovation shaping healthcare policy and drug development.
June’s pharmaceutical headlines reflect significant regulatory shifts, industry reorganization, and technological innovation shaping healthcare policy and drug development.
Early clinical successes, new research on immune toxicities, and expanding partnerships underscore the evolving landscape of cell and …
Big pharma pursues targeted expansion while trials in radiopharmaceuticals and immunotherapy highlight the breadth of innovation across cancer, …
A large phase III study known as SERENA-6 is attracting wide attention for challenging the way resistance is …
Sanofi’s acquisition of Blueprint Medicines, Eli Lilly’s gene-editing push, and several cross-continental alliances mark a new phase in …
U.S. regulators expand treatment options in prostate cancer as biotech innovators TRexBio and Spinogenix push forward with immune …
New pivotal trial milestones in multiple sclerosis and head and neck cancer, plus key collaboration and funding moves, …
Landmark ASCO results and advances in liquid biopsy-driven treatment switching spotlight innovation in cancer research and personalized medicine.
Several Phase 1 and Phase 2 trials report encouraging results this month, amplifying momentum in precision psychiatry, respiratory …
New data from India suggest that Hillchol, an oral cholera vaccine by Bharat Biotech, is safe, effective and …
Already a subscriber? Log in